长春中医药大学学报2025，Vol.41Issue(4)：461-466,6.DOI:10.13463/j.cnki.cczyy.2025.04.023
EGFR抑制剂联合KRAS G12C抑制剂治疗晚期结直肠癌的研究进展
Research progress of EGFR inhibitors combined with KRAS G12C inhibitors in the treatment of advanced colorectal cancer
摘要
Abstract
The incidence of Kirsten ratsarcoma viral oncogene(KRAS)mutations is 40％in colorectal cancer(CRC)patients.Among patients with CRC subtypes with such mutations,the prognosis of patients with KRAS G12C mutations is the worst.KRAS was previously considered an"undruggable"target,and for many years the treatment of such patients with CRC has been based on chemotherapy.Although the current treatment status has been improved to some extent by the emergence of epidermal growth factor receptor(EGFR)inhibitors,the phenomenon of drug resistance greatly affects the efficacy.At present,the launch of a variety of KRAS G12C inhibitors has brought new hope to clinical practice,but the efficacy of using this type of agents alone in the treatment of CRC is still low.In recent years,the combination of KRAS G12C inhibitors and EGFR inhibitors in the treatment of CRC has achieved good efficacy,and the safety is relatively high.The combination of the two can exert a synergistic effect,significantly improving the progression-free survival and objective response rate of patients.By consulting and sorting out relevant literature at home and abroad,this article reviews the clinical research on the combination of EGFR inhibitors and KRAS G12C inhibitors in the treatment of advanced CRC,providing new ideas for the treatment of advanced CRC in clinical practice.关键词
结直肠癌/实体瘤/鼠类肉瘤病毒癌基因/KRAS G12C抑制剂/EGFR抑制剂/联合治疗Key words
colorectal cancer/solid tumors/Kirsten ratsarcoma viral oncogene/KRAS G12C inhibitors/epidermal growth factor receptor inhibitors/combination therapy分类
医药卫生引用本文复制引用
黄程,肖中祥,苏博闻,吴天昊,赵毓,张广军..EGFR抑制剂联合KRAS G12C抑制剂治疗晚期结直肠癌的研究进展[J].长春中医药大学学报,2025,41(4):461-466,6.基金项目
四川省医院协会青年创新科研专项资金项目(Q23012) （Q23012）
